{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:52:35Z","timestamp":1793141555088,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","award":["Intramural Grant"],"award-info":[{"award-number":["Intramural Grant"]}],"id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40123-025-01157-4","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T02:52:30Z","timestamp":1749178350000},"page":"1661-1684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Systemic Effects of Intravitreal Anti-VEGF Therapy: A Review of Safety across Organ Systems"],"prefix":"10.1007","volume":"14","author":[{"given":"Mousumi","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikshya","family":"Moharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-5851","authenticated-orcid":false,"given":"Srikanta Kumar","family":"Padhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"6","key":"1157_CR1","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003\u201317.","journal-title":"Kidney Int"},{"issue":"2 Pt 2","key":"1157_CR2","first-page":"F240","volume":"268","author":"M Simon","year":"1995","unstructured":"Simon M, Gr\u00f6ne HJ, J\u00f6hren O, Kullmer J, Plate KH, Risau W, Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol. 1995;268(2 Pt 2):F240\u201350.","journal-title":"Am J Physiol"},{"issue":"26","key":"1157_CR3","doi-asserted-by":"publisher","first-page":"15809","DOI":"10.1073\/pnas.95.26.15809","volume":"95","author":"HH Marti","year":"1998","unstructured":"Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A. 1998;95(26):15809\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1157_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/path.1711770308","volume":"177","author":"HJ Gr\u00f6ne","year":"1995","unstructured":"Gr\u00f6ne HJ, Simon M, Gr\u00f6ne EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol. 1995;177(3):259\u201367.","journal-title":"J Pathol"},{"issue":"7","key":"1157_CR5","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1681\/ASN.V1171236","volume":"11","author":"S Thomas","year":"2000","unstructured":"Thomas S, Vanuystel J, Gruden G, Rodr\u00edguez V, et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol. 2000;11(7):1236\u201343.","journal-title":"J Am Soc Nephrol"},{"issue":"4\u20135","key":"1157_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1387\/ijdb.103214ec","volume":"55","author":"E Crivellato","year":"2011","unstructured":"Crivellato E. The role of angiogenic growth factors in organogenesis. Int J Dev Biol. 2011;55(4\u20135):365\u201375.","journal-title":"Int J Dev Biol"},{"issue":"5","key":"1157_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, Nagy A, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707\u201316.","journal-title":"J Clin Invest"},{"key":"1157_CR8","first-page":"11","volume":"463","author":"GE Palade","year":"1979","unstructured":"Palade GE, Simionescu M, Simionescu N. Structural aspects of the permeability of the microvascular endothelium. Acta Physiol Scand Suppl. 1979;463:11\u201332.","journal-title":"Acta Physiol Scand Suppl"},{"issue":"2","key":"1157_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3904\/kjim.2003.18.2.65","volume":"18","author":"BS Kim","year":"2003","unstructured":"Kim BS, Goligorsky MS. Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease. Korean J Intern Med. 2003;18(2):65\u201375.","journal-title":"Korean J Intern Med"},{"issue":"4","key":"1157_CR10","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.kint.2017.03.029","volume":"92","author":"H Kinashi","year":"2017","unstructured":"Kinashi H, Falke LL, Nguyen TQ, Bovenschen N, Aten J, Leask A, Ito Y, Goldschmeding R. Connective tissue growth factor regulates fibrosis-associated renal lymphangiogenesis. Kidney Int. 2017;92(4):850\u201363.","journal-title":"Kidney Int"},{"issue":"8","key":"1157_CR11","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1681\/ASN.2013070752","volume":"25","author":"D Veron","year":"2014","unstructured":"Veron D, Aggarwal PK, Velazquez H, Kashgarian M, et al. Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice. J Am Soc Nephrol. 2014;25(8):1814\u201324.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1157_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.ki.5002101","volume":"71","author":"HJ Baelde","year":"2007","unstructured":"Baelde HJ, Eikmans M, Lappin DW, Doran PP, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 2007;71(7):637\u201345.","journal-title":"Kidney Int"},{"issue":"1","key":"1157_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/157016110790226606","volume":"8","author":"K Doi","year":"2010","unstructured":"Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol. 2010;8(1):122\u20138.","journal-title":"Curr Vasc Pharmacol."},{"key":"1157_CR14","first-page":"455","volume":"59","author":"CS Melincovici","year":"2018","unstructured":"Melincovici CS, Bosca AB, Susman S, Marginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59:455\u201367.","journal-title":"Rom J Morphol Embryol"},{"issue":"15","key":"1157_CR15","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.3390\/ijms21155294","volume":"21","author":"M Braile","year":"2020","unstructured":"Braile M, Marcella S, Cristinziano L, Galdiero MR, et al. VEGF-A in cardiomyocytes and heart diseases. Int J Mol Sci. 2020;21(15):5294.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1157_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000491775","volume":"48","author":"YX Lv","year":"2018","unstructured":"Lv YX, Zhong S, Tang H, Luo B, et al. VEGF-A and VEGF-B coordinate the arteriogenesis to repair the infarcted heart with vagus nerve stimulation. Cell Physiol Biochem. 2018;48(2):433\u201349.","journal-title":"Cell Physiol Biochem"},{"key":"1157_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.738325","volume":"8","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhu X, Cui H, Shi J, et al. The role of the VEGF family in coronary heart disease. Front Cardiovasc Med. 2021;8: 738325.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1157_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jcb.21124","volume":"100","author":"A Brkovic","year":"2007","unstructured":"Brkovic A, Sirois MG. Vascular permeability induced by VEGF family members in vivo: role of endogenous PAF and NO synthesis. J Cell Biochem. 2007;100(3):727\u201337.","journal-title":"J Cell Biochem"},{"issue":"2","key":"1157_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s10753-018-0926-0","volume":"42","author":"G Lucarini","year":"2019","unstructured":"Lucarini G, Zizzi A, Rubini C, Ciolino F, et al. VEGF, microvessel density, and CD44 as inflammation markers in Peri-implant healthy mucosa, peri-implant mucositis, and peri-implantitis: impact of age, smoking, ppd, and obesity. Inflammation. 2019;42(2):682\u20139.","journal-title":"Inflammation"},{"issue":"41","key":"1157_CR20","doi-asserted-by":"publisher","first-page":"10351","DOI":"10.1073\/pnas.1801379115","volume":"115","author":"P Arjunan","year":"2018","unstructured":"Arjunan P, Lin X, Tang Z, Du Y, et al. VEGF-B is a potent antioxidant. Proc Natl Acad Sci U S A. 2018;115(41):10351\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1157_CR21","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1096\/fj.09-143180","volume":"24","author":"L Zentilin","year":"2010","unstructured":"Zentilin L, Puligadda U, Lionetti V, Zacchigna S, et al. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J. 2010;24(5):1467\u201378.","journal-title":"FASEB J"},{"issue":"6","key":"1157_CR22","doi-asserted-by":"publisher","first-page":"H789","DOI":"10.1152\/ajpheart.00559.2013","volume":"306","author":"T Zhao","year":"2014","unstructured":"Zhao T, Zhao W, Meng W, Liu C, et al. Vascular endothelial growth factor-C: its unrevealed role in fibrogenesis. Am J Physiol Heart Circ Physiol. 2014;306(6):H789\u201396.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"1157_CR23","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1172\/JCI97192","volume":"128","author":"JM Vieira","year":"2018","unstructured":"Vieira JM, Norman S, Villa Del Campo C, Cahill TJ, et al. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. J Clin Invest. 2018;128(8):3402\u201312.","journal-title":"J Clin Invest"},{"key":"1157_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.109162","volume":"222","author":"M Lamminsalo","year":"2022","unstructured":"Lamminsalo M, Urtti A, Ranta VP. Quantitative pharmacokinetic analyses of anterior and posterior elimination routes of intravitreal anti-VEGF macromolecules using published human and rabbit data. Exp Eye Res. 2022;222: 109162.","journal-title":"Exp Eye Res"},{"issue":"1","key":"1157_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2018-000185","volume":"4","author":"PK Kaiser","year":"2019","unstructured":"Kaiser PK, Kodjikian L, Korobelnik JF, Winkler J, Torri A, Zeitz O, et al. Systemic pharmacokinetic\/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ Open Ophthalmol. 2019;4(1): e000185.","journal-title":"BMJ Open Ophthalmol"},{"issue":"7","key":"1157_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1389200216666151001120831","volume":"16","author":"F Semeraro","year":"2015","unstructured":"Semeraro F, Morescalchi F, Duse S, Gambicorti E, Cancarini A, Costagliola C. Pharmacokinetic and pharmacodynamic properties of Anti-VEGF drugs after intravitreal injection. Curr Drug Metab. 2015;16(7):572\u201384.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"1157_CR27","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond). 2018;32(6):1010\u201320.","journal-title":"Eye (Lond)"},{"issue":"10","key":"1157_CR28","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358.","journal-title":"Retina"},{"issue":"3","key":"1157_CR29","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1167\/iovs.09-4140","volume":"51","author":"T Miyake","year":"2010","unstructured":"Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51(3):1606\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"1157_CR30","first-page":"3025","volume":"53","author":"J Gaudreault","year":"2012","unstructured":"Gaudreault J, Gunde T, Floyd HS, Ellis J, Tietz J, Binggeli D, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(14):3025.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1157_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/tvst.13.11.14","volume":"13","author":"C Diack","year":"2024","unstructured":"Diack C, Gibiansky L, Jaminion F, Gibiansky E, Gaudreault J, Bogman K, et al. Ocular pharmacokinetics of faricimab following intravitreal administration in patients with retinal disease. Transl Vis Sci Technol. 2024;13(11):14.","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"1157_CR32","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358.","journal-title":"Retina"},{"issue":"3","key":"1157_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","volume":"96","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Barsoum M, Arman F, Selamet U, et al. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572\u201380.","journal-title":"Kidney Int"},{"issue":"3","key":"1157_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1681\/ASN.2005080810","volume":"17","author":"V Eremina","year":"2006","unstructured":"Eremina V, Cui S, Gerber H, et al. Vascular endothelial growth factor A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol. 2006;17(3):724\u201335.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1157_CR35","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1681\/ASN.2014010060","volume":"26","author":"H Dimke","year":"2015","unstructured":"Dimke H, Sparks MA, Thomson BR, Frische S, et al. Tubulovascular cross-talk by vascular endothelial growth factor A maintains peritubular microvasculature in kidney. J Am Soc Nephrol. 2015;26(5):1027\u201338.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1157_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039580","volume":"7","author":"FG Machado","year":"2012","unstructured":"Machado FG, Kuriki PS, Fujihara CK, et al. Chronic VEGF blockade worsens glomerular injury in the remnant kidney model. PLoS One. 2012;7(6): e39580.","journal-title":"PLoS One"},{"key":"1157_CR37","doi-asserted-by":"publisher","DOI":"10.31661\/gmj.v7i0.1299","volume":"7","author":"S Bagheri","year":"2018","unstructured":"Bagheri S, Dormanesh B, Afarid M, Sagheb MM. Proteinuria and renal dysfunction after intravitreal injection of bevacizumab in patients with diabetic nephropathy: a prospective observational Study. Galen Med J. 2018;7: e1299.","journal-title":"Galen Med J"},{"issue":"3","key":"1157_CR38","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1167\/iovs.17-22853","volume":"59","author":"AR Glassman","year":"2018","unstructured":"Glassman AR, Liu D, Jampol LM, Sun JK, Diabetic Retinopathy Clinical Research Network. Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(3):1199\u2013205.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"1","key":"1157_CR39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12882-019-1650-1","volume":"20","author":"RA O\u2019Neill","year":"2019","unstructured":"O\u2019Neill RA, Gallagher P, Douglas T, Little JA, et al. Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol. 2019;20(1):478.","journal-title":"BMC Nephrol"},{"issue":"12","key":"1157_CR40","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.18632\/aging.204133","volume":"14","author":"SF Yang","year":"2022","unstructured":"Yang SF, Su YC, Lim CC, Huang JY, Hsu SM, Wu LW, Chang YS, Hung JH. Risk of dialysis in patients receiving intravitreal anti-vascular endothelial growth factor treatment: a population-based cohort study. Aging (Albany NY). 2022;14(12):5116\u201330.","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"1157_CR41","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1007\/s00210-023-02910-x","volume":"397","author":"CH Chen","year":"2024","unstructured":"Chen CH, Lim PS, Wu TK, Chuang WL, Yu TS, Tsai FJ, Chen CM, Chang KH. Intravitreal ranibizumab injection is associated with an increased risk of chronic kidney disease: a population-based study in Taiwan. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(7):4799\u2013808.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"8","key":"1157_CR42","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.oret.2024.03.014","volume":"8","author":"CX Cai","year":"2024","unstructured":"Cai CX, Nishimura A, Bowring MG, Westlund E, et al. Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics Network Study. Ophthalmol Retina. 2024;8(8):733\u201343.","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"1157_CR43","doi-asserted-by":"publisher","first-page":"100326","DOI":"10.1016\/j.xops.2023.100326","volume":"3","author":"CC Bunge","year":"2023","unstructured":"Bunge CC, Dalal PJ, Gray E, Culler K, Brown JJ, Quaggin SE, et al. The association of intravitreal Anti-VEGF injections with kidney function in diabetic retinopathy. Ophthalmol Sci. 2023;3(4):100326.","journal-title":"Ophthalmol Sci."},{"issue":"6","key":"1157_CR44","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","volume":"13","author":"M Shye","year":"2020","unstructured":"Shye M, Hanna RM, Patel SS, et al. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J. 2020;13(6):969\u201380.","journal-title":"Clin Kidney J"},{"issue":"7","key":"1157_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.579603","volume":"7","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Tran NT, Patel SS, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use. Front Med. 2020;7(7): 579603.","journal-title":"Front Med"},{"issue":"6","key":"1157_CR46","first-page":"653","volume":"37","author":"E Morales","year":"2017","unstructured":"Morales E, Moliz C, Gutierrez E. Renal damage associated to intravitreal administration of ranibizumab. Nefrol Engl Ed. 2017;37(6):653\u20135.","journal-title":"Nefrol Engl Ed"},{"issue":"4","key":"1157_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/08998280.2021.1885285","volume":"34","author":"M Ahmed","year":"2021","unstructured":"Ahmed M, Alouch N, Ahmed A, Jagadesh SK. Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections. Bayl Univ Med Cent Proc. 2021;34(4):527\u20139.","journal-title":"Bayl Univ Med Cent Proc"},{"issue":"1","key":"1157_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bcp.15558","volume":"89","author":"G Gan","year":"2023","unstructured":"Gan G, Michel M, Max A, Sujet-Perone N, Zevering Y, Vermion JC, Zaidi M, Savenkoff B, Perone JM. Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: a case report and review of the literature. Br J Clin Pharmacol. 2023;89(1):401\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1157_CR49","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1038\/s41598-023-34128-5","volume":"13","author":"YI Chou","year":"2023","unstructured":"Chou YI, Chang HY, Lin MY, Tseng CH, Wang TJ, Lin IC. Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections. Sci Rep. 2023;13(1):7597.","journal-title":"Sci Rep"},{"issue":"13","key":"1157_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010198","volume":"97","author":"JW Kwon","year":"2018","unstructured":"Kwon JW, Jee D, La TY. The association between myocardial infarction and intravitreal bevacizumab injection. Medicine (Baltimore). 2018;97(13): e0198.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"1157_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41433-021-01416-1","volume":"36","author":"YY Chen","year":"2022","unstructured":"Chen YY, Lai YJ, Yen YF, Chou P. Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction. Eye (Lond). 2022;36(1):153\u20139.","journal-title":"Eye (Lond)"},{"issue":"1","key":"1157_CR52","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.1038\/s41598-023-34128-5","volume":"13","author":"YI Chou","year":"2023","unstructured":"Chou YI, Chang HY, Lin MY, Tseng CH, Wang TJ, Lin IC. Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections. Sci Rep. 2023;13(1):7597.","journal-title":"Sci Rep"},{"issue":"4","key":"1157_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s13300-024-01544-3","volume":"15","author":"JYM Lai","year":"2024","unstructured":"Lai JYM, Riley DR, Anson M, Henney A, Cuthbertson DJ, Hernadez G, et al. Cardiovascular outcomes with intravitreal anti-vascular endothelial growth factor therapy in patients with diabetes: a real-world data analysis. Diabetes Ther. 2024;15(4):833\u201342.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1157_CR54","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12872-024-04095-4","volume":"24","author":"Y Sui","year":"2024","unstructured":"Sui Y, Zhao Y, Zhou N, Sun H, Sun Y, Liu J. Case report: heart failure related to intravitreal injection of anti-VEGF. BMC Cardiovasc Disord. 2024;24(1):418.","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"1157_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0640","volume":"139","author":"N Ngo Ntjam","year":"2021","unstructured":"Ngo Ntjam N, Thulliez M, Paintaud G, Salvo F, Angoulvant D, Pisella PJ, et al. Cardiovascular adverse events with intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of Randomized Clinical Trials. JAMA Ophthalmol. 2021;139(6):1\u201311.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"1157_CR56","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/ndt\/gfac305","volume":"38","author":"JS Lees","year":"2023","unstructured":"Lees JS, Dobbin SJH, Elyan BMP, Gilmour DF, Tomlinson LP, Lang NN, Mark PB. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrol Dial Transplant. 2023;38(7):1666\u201381.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1157_CR57","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ophtha.2024.07.008","volume":"132","author":"JM Yang","year":"2025","unstructured":"Yang JM, Jung SY, Kim MS, Lee SW, Yon DK, Shin JI, et al. Cardiovascular and cerebrovascular adverse events associated with intravitreal Anti-VEGF monoclonal antibodies: a World Health Organization Pharmacovigilance Study. Ophthalmology. 2025;132(1):62\u201378.","journal-title":"Ophthalmology"},{"issue":"8","key":"1157_CR58","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1097\/IAE.0000000000003066","volume":"41","author":"SK Ray","year":"2021","unstructured":"Ray SK, Manz SN. Brain health assessment in macular degeneration patients undergoing intravitreal anti-vascular endothelial growth factor injections (The Bham Study): an Interim analysis. Retina. 2021;41(8):1748\u201353.","journal-title":"Retina"},{"issue":"5","key":"1157_CR59","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3928\/23258160-20190503-14","volume":"50","author":"MR Starr","year":"2019","unstructured":"Starr MR, Dalvin LA, AbouChehade JE, Damento GM, Garcia MD, Shah SM, Hodge DO, Meissner I, Iezzi R, Bakri SJ. Classification of strokes in patients receiving intravitreal anti-vascular endothelial growth factor. Ophthalmic Surg Lasers Imaging Retina. 2019;50(5):e140\u201357.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"5","key":"1157_CR60","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","volume":"137","author":"LA Dalvin","year":"2019","unstructured":"Dalvin LA, Starr MR, AbouChehade JE, et al. Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137(5):483\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"1157_CR61","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2020.00315","volume":"11","author":"J Sultana","year":"2020","unstructured":"Sultana J, Scondotto G, Cutroneo PM, Morgante F, Trifir\u00f2 G. Intravitreal anti-VEGF drugs and signals of dementia and Parkinson-like events: analysis of the VigiBase database of spontaneous reports. Front Pharmacol. 2020;11:315.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1157_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s13256-021-02983-3","volume":"15","author":"M Yoshimoto","year":"2021","unstructured":"Yoshimoto M, Takeda N, Yoshimoto T, Matsumoto S. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report. J Med Case Rep. 2021;15(1):403.","journal-title":"J Med Case Rep"},{"issue":"10","key":"1157_CR63","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30185","volume":"14","author":"NA Fugara","year":"2022","unstructured":"Fugara NA, Shawareb ZA, Rakkad NK, Barhoum ML, Shawareb BA, Al-Madani MM, Al-Madani MV. The risk of non-arteritic ischemic optic neuropathy post-intravitreal bevacizumab injection. Cureus. 2022;14(10): e30185. https:\/\/doi.org\/10.7759\/cureus.30185.","journal-title":"Cureus"},{"issue":"2","key":"1157_CR64","first-page":"15","volume":"2","author":"A Basilious","year":"2023","unstructured":"Basilious A, Muni RH, Juncal VR. Anti-VEGF therapy in pregnancy and breastfeeding. Can Eye Care Today. 2023;2(2):15\u20139.","journal-title":"Can Eye Care Today"},{"issue":"6","key":"1157_CR65","doi-asserted-by":"publisher","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","volume":"280","author":"N Ferrara","year":"2001","unstructured":"Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280(6):C1358\u201366.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"1157_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14767050802645035","volume":"22","author":"G Galazios","year":"2009","unstructured":"Galazios G, Papazoglou D, Tsikouras P, Kolios G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med. 2009;22(5):371\u20138.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"10","key":"1157_CR67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/jop.2015.0056","volume":"31","author":"S Polizzi","year":"2015","unstructured":"Polizzi S, Mahajan VB. Intravitreal Anti-VEGF injections in pregnancy: case series and review of literature. J Ocul Pharmacol Ther. 2015;31(10):605\u201310.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"1157_CR68","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/eye.2017.305","volume":"32","author":"P Fossum","year":"2018","unstructured":"Fossum P, Couret C, Briend B, Weber M, Lagarce L. Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases. Eye (Lond). 2018;32(4):830\u20132.","journal-title":"Eye (Lond)"},{"issue":"5","key":"1157_CR69","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41433-023-02811-6","volume":"38","author":"AY Ong","year":"2024","unstructured":"Ong AY, Kiire CA, Frise C, Bakr Y, de Silva SR. Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature. Eye (Lond). 2024;38(5):951\u201363.","journal-title":"Eye (Lond)"},{"issue":"4","key":"1157_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01572.x","volume":"88","author":"P Petrou","year":"2010","unstructured":"Petrou P, Georgalas I, Giavaras G, et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88(4): e136.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1157_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/21556660.2020.1847926","volume":"10","author":"F Kianersi","year":"2021","unstructured":"Kianersi F, Ghanbari H, Naderi Beni Z, Naderi BA. Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy. J Drug Assess. 2021;10(1):7\u20139.","journal-title":"J Drug Assess"},{"issue":"4","key":"1157_CR72","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/eye.2013.311","volume":"28","author":"L Sullivan","year":"2014","unstructured":"Sullivan L, Kelly SP, Glenn A, Williams CP, McKibbin M. Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond). 2014;28(4):492\u20134.","journal-title":"Eye (Lond)"},{"issue":"12","key":"1157_CR73","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636\u201341.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1157_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000324057","volume":"76","author":"T Ozgurtas","year":"2011","unstructured":"Ozgurtas T, Aydin I, Turan O, Koc E, Hirfanoglu IM, Acikel CH, Akyol M, Serdar M, Erbil KM. Soluble vascular endothelial growth factor receptor 1 in human breast milk. Hormone Res Paediat. 2011;76(1):17\u201321.","journal-title":"Hormone Res Paediat"},{"issue":"8","key":"1157_CR75","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1097\/IAE.0000000000000517","volume":"35","author":"TJ McFarland","year":"2015","unstructured":"McFarland TJ, Rhoads AD, Hartzell M, Emerson GG, Bhavsar AR, Stout JT. Bevacizumab levels in breast milk after long-term intravitreal injections. Retina. 2015;35(8):1670\u20133.","journal-title":"Retina"},{"key":"1157_CR76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13006-022-00463-y","volume":"17","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zhou R, Sun Z, Zheng Y, Lin B. Vascular endothelial growth factor-A level in human breast milk after intravitreal injection of ranibizumab: a case report. Int Breastfeed J. 2022;17:25.","journal-title":"Int Breastfeed J"},{"issue":"10","key":"1157_CR77","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"R Avery","year":"2017","unstructured":"Avery R, Castellarin A, Steinle N, Dhoot D, Pieramici D, See R, et al. Systemic pharmacokinetics and pharmacodynamics of afibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358.","journal-title":"Retina"},{"key":"1157_CR78","doi-asserted-by":"crossref","unstructured":".Hapsari D, Sitorus RS. Intravitreal bevacizumab in retinopathy of prematurity: inject or not? Asia Pac J Ophthalmol. 2014;3(6):368\u201378.","DOI":"10.1097\/APO.0000000000000039"},{"issue":"2","key":"1157_CR79","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98(2):F170\u20134.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3","key":"1157_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230678","volume":"15","author":"M Arima","year":"2020","unstructured":"Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, Nakama T, Tsukamoto S, Ochiai M, Ohga S, Sonoda KH. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS One. 2020;15(3): e0230678.","journal-title":"PLoS One"},{"key":"1157_CR81","doi-asserted-by":"crossref","unstructured":".Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, Eyal F. Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up. Am J Perinatol. 2021;38(11):1158\u201366.","DOI":"10.1055\/s-0040-1710556"},{"issue":"1","key":"1157_CR82","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40942-021-00340-6","volume":"7","author":"M Abrishami","year":"2021","unstructured":"Abrishami M, Boskabadi H, Abrishami M, Shekarchian F, Khadem-Rezaiyan M, Shoeibi N. Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case-control study. Int J Retina Vitreous. 2021;7(1):68.","journal-title":"Int J Retina Vitreous"},{"key":"1157_CR83","doi-asserted-by":"publisher","first-page":"1077137","DOI":"10.3389\/fped.2022.1077137","volume":"10","author":"J Chen","year":"2023","unstructured":"Chen J, Hao Q, Zhang J, Du Y, Chen H, Cheng X. Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity. Front Pediatr. 2023;10:1077137.","journal-title":"Front Pediatr"},{"issue":"5","key":"1157_CR84","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","volume":"137","author":"LA Dalvin","year":"2019","unstructured":"Dalvin LA, Starr MR, AbouChehade JE, Damento GM, Garcia M, Shah SM, et al. Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137(5):483\u201390.","journal-title":"JAMA Ophthalmol."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01157-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:06:16Z","timestamp":1757181976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01157-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Srikanta Kumar Padhy, Sikshya Moharana, and Mousumi Banerjee have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}